Incyte Corporation and TG Therapeutics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: Incyte vs. TG Therapeutics

In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Incyte Corporation and TG Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Incyte's SG&A expenses have surged by approximately 600% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, TG Therapeutics, while experiencing a significant increase in 2020, has maintained a more conservative growth, with expenses rising by about 400% over the same period.

Key Insights

• Incyte's Growth: By 2023, Incyte's SG&A expenses reached nearly 1.16 billion, a testament to its robust market presence.
• TG Therapeutics' Strategy: Despite a peak in 2021, TG Therapeutics' expenses stabilized, indicating a strategic pivot.

These trends highlight the differing strategies of these biotech firms, offering insights into their operational priorities and market positioning.